US Stock MarketDetailed Quotes
INO Inovio Pharmaceuticals
- 4.3200
- +0.1300+3.10%
Close Nov 29 13:00 ET
- 4.4000
- +0.0800+1.85%
Post 16:29 ET
112.75MMarket Cap-975P/E (TTM)
4.3390High4.2010Low171.10KVolume4.2400Open4.1900Pre Close732.59KTurnover0.72%Turnover RatioLossP/E (Static)26.10MShares14.748052wk High1.53P/B103.16MFloat Cap3.850052wk Low--Dividend TTM23.88MShs Float2352.0000Historical High--Div YieldTTM3.29%Amplitude3.8500Historical Low4.2810Avg Price1Lot Size
Inovio Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | -55.41%100.76K | 0 | -91.89%832.01K | -17.66%102.65K | -95.76%388.45K | -71.19%225.97K | -42.26%114.94K | 478.23%10.26M | -85.14%124.67K |
| Operating revenue | --0 | -55.41%100.76K | --0 | -91.89%832.01K | -17.66%102.65K | -95.76%388.45K | -71.19%225.97K | -42.26%114.94K | 478.23%10.26M | -85.14%124.67K |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 7.55%27.35M | -10.65%33.3M | -28.55%31.48M | -51.68%134.26M | -50.96%27.5M | -43.38%25.43M | -64.48%37.27M | -38.74%44.07M | -8.30%277.84M | -47.28%56.07M |
| Selling and administrative expenses | -13.21%8.61M | -24.52%10.21M | -23.90%10.57M | -47.24%47.58M | -26.58%10.24M | -16.06%9.93M | -72.09%13.52M | -12.93%13.89M | 67.78%90.19M | -0.70%13.95M |
| -General and administrative expense | -13.21%8.61M | -24.52%10.21M | -23.90%10.57M | -47.24%47.58M | -26.58%10.24M | -16.06%9.93M | -72.09%13.52M | -12.93%13.89M | 67.78%90.19M | -0.70%13.95M |
| Research and development costs | 20.84%18.73M | -2.75%23.09M | -30.70%20.91M | -53.81%86.68M | -59.04%17.25M | -53.14%15.5M | -57.95%23.74M | -46.09%30.18M | -24.71%187.65M | -54.37%42.12M |
| Operating profit | -9.22%-27.35M | 10.38%-33.2M | 28.37%-31.48M | 50.13%-133.43M | 51.04%-27.39M | 29.97%-25.04M | 64.43%-37.04M | 38.73%-43.95M | 11.17%-267.57M | 46.97%-55.95M |
| Net non-operating interest income expense | -31.90%1.11M | -29.51%1.31M | -30.16%1.32M | 95.87%6.91M | -2.44%1.54M | 54.45%1.63M | 240.83%1.85M | 431.45%1.89M | 147.30%3.53M | 275.83%1.58M |
| Non-operating interest income | -42.91%1.11M | -39.70%1.31M | -32.03%1.5M | 70.08%8.13M | -3.69%1.82M | 41.95%1.94M | 152.81%2.17M | 229.52%2.21M | 42.19%4.78M | 109.99%1.89M |
| Non-operating interest expense | --0 | --0 | -43.27%177.83K | -2.49%1.22M | -9.94%282.33K | 0.00%313.49K | 0.00%313.49K | 0.00%313.49K | -35.24%1.25M | -34.73%313.49K |
| Other net income (expense) | 110.23%1.08M | 0.18%-347.54K | -121.81%-307.36K | 36.79%-8.6M | 1,024.61%853.29K | -241.51%-10.52M | 92.90%-348.18K | 125.47%1.41M | -296.37%-13.61M | 95.03%-92.29K |
| Gain on sale of security | 706.74%1.33M | -102.26%-20.82K | -84.44%500.88K | 174.57%5.85M | -30.99%1.93M | 88.04%-219.34K | 123.26%922.94K | 166.48%3.22M | -143.46%-7.85M | 235.93%2.79M |
| Earnings from equity interest | 51.25%324.25K | -313.27%-334.29K | -120.44%-126.02K | 140.70%773.15K | -74.70%-214.61K | 170.27%214.37K | 116.78%156.75K | 214.67%616.64K | -243.16%-1.9M | -711.62%-122.85K |
| Special income (charges) | --0 | ---- | ---- | ---10.51M | --0 | ---10.51M | ---- | ---- | --0 | --0 |
| -Less:Impairment of capital assets | --0 | ---- | ---- | --10.51M | --0 | --10.51M | ---- | ---- | --0 | --0 |
| Other non- operating income (expenses) | -20,416.01%-579.82K | 100.53%7.57K | 71.88%-682.22K | -22.01%-4.71M | 68.86%-860.91K | 100.30%2.85K | -46,746.03%-1.43M | -1,480.57%-2.43M | -1,224.61%-3.86M | -1,656.49%-2.76M |
| Income before tax | 25.83%-25.17M | 9.28%-32.24M | 25.04%-30.47M | 51.34%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 47.15%-40.65M | 8.43%-277.65M | 49.07%-54.46M |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -398.45%-2.17M | --0 |
| Net income | 25.83%-25.17M | 9.28%-32.24M | 25.04%-30.47M | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M |
| Net income continuous Operations | 25.83%-25.17M | 9.28%-32.24M | 25.04%-30.47M | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 25.83%-25.17M | 9.28%-32.24M | 25.04%-30.47M | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 25.83%-25.17M | 9.28%-32.24M | 25.04%-30.47M | 51.71%-135.12M | 54.09%-25M | 10.20%-33.93M | 67.25%-35.53M | 48.59%-40.65M | 7.85%-279.82M | 49.07%-54.46M |
| Basic earnings per share | 41.45%-0.89 | 26.09%-1.19 | 30.69%-1.31 | 56.72%-6.09 | 57.65%-1.08 | 15.56%-1.52 | 70.83%-1.61 | 56.25%-1.89 | 19.37%-14.07 | 57.85%-2.55 |
| Diluted earnings per share | 41.45%-0.89 | 26.09%-1.19 | 30.69%-1.31 | 56.72%-6.09 | 57.65%-1.08 | 15.56%-1.52 | 70.83%-1.61 | 56.25%-1.89 | 19.37%-14.07 | 57.85%-2.55 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
